CLINICAL_TRIALS ClinicalTrials.gov record with results posted

Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04256707
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-10-10T00:02:24.490356+00:00
Published At: 2026-10-09T00:00:00+00:00
Record Updated At: 2026-10-09
Results Posted At: 2026-10-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Small Cell Lung Carcinoma (NSCLC)", "Colorectal Cancer (CRC)", "Other Solid Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-10-09"
protocolSection.identificationModule.nctId: "NCT04256707"
protocolSection.identificationModule.officialTitle: "Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-10-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.